Ayşe Bilge ÖZTÜRK
(Koç Üniversitesi, Tıp Fakültesi, Alerji ve Klinik İmmünoloji Anabilim Dalı, İstanbul, Türkiye)
(Kırıkkale Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Alerji ve Klinik İmmünoloji Bilim Dalı, Kırıkkale, Türkiye)
(Hacettepe Üniversitesi, Tıp Fakültesi, Pediatrik Alerji Anabilim Dalı, Ankara, Türkiye)
(Ankara Şehir Hastanesi, Çocuk Alerji ve İmmünoloji Anabilim Dalı, Ankara, Türkiye)
Bülent Enis ŞEKEREL
(Hacettepe Üniversitesi, Tıp Fakültesi, Pediatrik Alerji Anabilim Dalı, Ankara, Türkiye)
(Ankara Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Alerji ve Klinik İmmünoloji Bilim Dalı, Ankara, Türkiye)
Yıl: 2021Cilt: 19Sayı: 1ISSN: 1308-9234Sayfa Aralığı: 1 - 5İngilizce

42 0
Pros and Cons of Nebulizer Treatment in Asthma Exacerbation During the COVID-19 Pandemic
Nebulizers generate aerosols and may potentially transmit respiratory viral particles including SARS-CoV-2. There is a great concernabout the use of a nebulizer in the treatment of asthma exacerbations in the hospital or home setting during the COVID-19 pandemicand its use is not recommended unless essential. However, aerosol therapy should not be avoided in obligatory indications. Therefore,indications of nebulizer use during the pandemic should be evaluated on an individual basis in case of a severe asthma attack, andinfection control recommendations should be followed by clinicians while using nebulizers. In this article, we aimed to assess the safetyin addition to the “pro” and “con” sides of nebulizer treatment in asthma exacerbation during the COVID-19 pandemic.
DergiDerlemeErişime Açık
  • 1. Global strategy for asthma management and prevention. Global Initiative for Asthma Web site. http://www.ginasthma. org. Updated 2020. Accessed December 20, 2020.
  • 2. Türkiye Ulusal Allerji ve Klinik İmmünoloji Derneği ve Türk Toraks Derneği. Astım Tanı ve Tedavi Rehberi 2020 Güncellemesi. Çelik G (ed). Aralık 2020.
  • 3. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127(1):335-71.
  • 4. Ozturk AB, Baççıoğlu A, Soyer O, Civelek E, Şekerel BE, Bavbek S. Change in allergy practice during the COVID-19 pandemic. Int Arch Allergy Immunol 2021;182(1):49-52.
  • 5. Amirav I, Newhouse MT. Transmission of coronavirus by nebulizer: A serious, underappreciated risk. CMAJ 2020;192:E346.
  • 6. Soyer Ö, Kahveci M, Büyüktiryaki B, Arık Yılmaz E, Karaatmaca B, Esenboğa S, et al. Mesh nebulizer is as effective as jet nebulizer in clinical practice of acute asthma in children. Turk J Med Sci 2019;49(4):1008-13.
  • 7. Hui DS, Chow BK, Chu LC, Ng SS, Hall SD, Gin T, et al. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009;135:648-54.
  • 8. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature 2020;582:557-60.
  • 9. Wan GH, Tsai YH, Wu YK, Tsao KC. A large volume nebulizer would not be an infectious source for severe acute respiratory syndrome. Infect Control Hosp Edidemiol 2004;25:1113-5.
  • 10. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382(16):1564-7.
  • 11. Heinzerling A, Stuckey MJ, Scheuer T, Xu K, Perkins KM, Resseger H, et al. Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient - Solano County, California, February 2020. MMWR Morb Mortal Wkly Rep 2020:17;69(15):472-6.
  • 12. Tang JW, Li Y, Eames I, Chan PKS, Ridgway GL. Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises. J Hosp Infect 2006;64:100– 14.
  • 13. Tang JW, Kalliomaki P, Varila TM, Waris M, Koskela H. Nebulisers as a potential source of airborne virus. J Infect 2020; 81(4): 647–9.
  • 14. Ari A. Use of aerosolised medications at home for COVID-19. Lancet Respir Med 2020;8(8):754-6.
  • 15. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: severe asthma. [Internet]. 2020. Available from: https://www.guidelines.co.uk/covid-19-rapidguideline-severeasthma/455275.article
  • 16. Ozturk AB, Bavbek S. Role of SARS-CoV-2 in asthma exacerbations. Asthma Allergy Immunol 2020;18 (Supplement 1): 8-10.
  • 17. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med 2020;167:105987.
  • 18. Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev 2013;2013(9):CD000052.
  • 19. Chinese Medical Association Respiratory Branch, Expert consensus on protective measures related to respiratory therapy in patients with severe and critical coronavirus infection. Chin J Tuberc Respir Dis 2020;17:E020.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.